YCBD stock forecast, quote, news & analysis
cbdMD Inc is a United States based company... Show more
cbdMD (YCBD) Stock Analysis: Building a Broader Wellness Platform Beyond Hemp
Key Takeaways
- YCBD shares rose roughly 5% over the trailing 30 days, moving from about $0.39 to near $0.42, a modest move relative to the stock's historically elevated volatility.
- The stock remains in a longer-term downtrend, trading near the lower end of a 52-week range of $0.33 to $2.56, with a market capitalization near $4.7 million and a beta of approximately 2.4.
- cbdMD completed its acquisition of Twinlab's operating assets and brands in early November 2026, diversifying the business beyond hemp into legacy vitamins, supplements, and wellness.
- Fiscal 2026 third-quarter net sales grew 20% year over year to $5.6 million, led by 61% wholesale growth and accelerating momentum in the Oasis beverage line.
- Federal hemp regulation remains the central risk, with a stricter THC limit scheduled to take effect November 12, 2026, pending potential legislative changes.
- For deeper data on valuation and fundamentals, explore cbdMD's Price Targets, Earnings, and Forecast on dedicated pages.
- See how top-performing automated strategies are being applied to stocks like YCBD by visiting Tickeron's Trending AI Robots.
Current Market Snapshot
cbdMD, Inc. trades on the NYSE American exchange as a micro-cap wellness company, with shares closing near $0.42 in early November 2026. Over the trailing 30 days, the stock has moved modestly higher, gaining approximately 5% after a period of choppy, low-liquidity trading. This muted move stands in contrast to the wider swings that have characterized YCBD over the past year, when the stock traded from a 52-week high above $2.50 down to lows near $0.33.
With a market capitalization of roughly $4.7 million and a beta near 2.4, YCBD is a high-risk, high-volatility name that tends to react sharply to company-specific and sector-wide headlines. Investor attention has centered on the company's pivot toward a broader consumer wellness portfolio, as well as the evolving regulatory outlook for hemp-derived products.
cbdMD (YCBD) Business Overview and Competitive Position
Headquartered in Charlotte, North Carolina, cbdMD is a consumer wellness company whose portfolio spans multiple hemp-derived and mainstream wellness brands. Its core cbdMD line includes CBD oils, gummies, capsules, topicals, and compliant Delta-9 THC products, while the Paw CBD brand serves the pet wellness market and the ATRx line offers functional mushroom supplements. The Oasis brand markets hemp-derived THC beverages, and the company's Bluebird Botanicals brand, acquired in January 2026, adds a long-standing CBD brand with a recognized retail and e-commerce presence.
The company distributes through direct-to-consumer channels, e-commerce marketplaces, and a growing wholesale and retail network. A key competitive focus is compliance and transparency: cbdMD emphasizes third-party testing, quality standards, and, more recently, a self-affirmed GRAS determination supporting its CBD safety data. Management has positioned the company as a consolidator in a fragmented wellness category, using its NYSE American listing and in-house marketing infrastructure to integrate acquired brands.
Recent Developments Driving YCBD
The most significant recent catalyst was the completion, announced on November 2, 2026, of cbdMD's acquisition of the operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and ResVitale. The assets were acquired through a Florida Chapter 727 assignment for the benefit of creditors. The transaction brings decades-old supplement brands into the portfolio and, importantly, reduces cbdMD's reliance on hemp-derived products at a time of regulatory uncertainty in that category.
The Twinlab deal followed the company's September 2026 announcement that it had entered a definitive agreement for the acquisition. Management indicated the combined portfolio was expected to lift revenue toward approximately $30 million annually. Around the same period, cbdMD was downgraded to Hold from Buy by Maxim.
On the operating side, fiscal 2026 third-quarter results reported in August showed net sales up 20% year over year to $5.6 million, with the wholesale channel growing 61% and Oasis beverage depletions accelerating. However, gross margin narrowed to 54.7% from 61.5% a year earlier amid a shift toward lower-margin wholesale and regulatory-related repacking and testing costs, and the company launched a cost-reduction program targeting $100,000 to $150,000 in monthly savings.
Regulatory developments remain the dominant external factor. Section 781 of H.R. 5371 is scheduled to impose a 0.4 milligram THC-per-container limit on hemp-derived consumables nationally on November 12, 2026, pending possible legislative changes. Management has been actively supporting bipartisan proposals that would soften or replace those restrictions.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies drawn from a much larger universe of AI-driven bots that trade thousands of tickers. Only the top-performing and most relevant robots are featured in this section, helping traders cut through the noise. The bots differ widely in approach, holding period, and performance metrics, ranging from short-term momentum strategies to longer-horizon trend models. For investors monitoring volatile micro-cap names like cbdMD, the section offers a way to observe how quantitative systems are positioning across the market. Browsing the page can provide additional context for anyone looking to complement fundamental research with systematic, data-driven signals.
2026 Outlook and What Investors Should Watch
Looking ahead, the central question for cbdMD is whether the pending November 12, 2026 federal THC limit will take effect as written or be revised through bipartisan legislation. A restrictive outcome could pressure the company's Delta-9 and Oasis beverage revenue, while a favorable regulatory fix would remove a major overhang and likely benefit well-capitalized, compliance-focused operators.
Investors should also track the integration and financial contribution of the Twinlab brands, which are expected to materially expand revenue and diversify the business beyond hemp. Management has signaled that integration details and combined-company guidance will arrive in upcoming earnings communications. Margin recovery, the pace of cost-reduction savings, and progress toward the company's stated cash-breakeven revenue target in the low-to-mid $6 million per-quarter range are additional metrics to monitor.
Broader themes, including state-level shipping and labeling restrictions, wholesale channel mix, and consumer demand for wellness products, will continue to shape results. As a micro-cap with a beta near 2.4, YCBD is also sensitive to general market sentiment and liquidity conditions. Investors should weigh these factors carefully and avoid treating any single data point as a definitive signal.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
YCBD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for YCBD turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Indicator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on YCBD as a result. In 85 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where YCBD advanced for three days, in 148 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 33 cases where YCBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
YCBD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for YCBD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.568) is normal, around the industry mean (6.379). P/E Ratio (1.809) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of beauty shops
Industry PharmaceuticalsGeneric